Promising Results from Alzheimer's Disease Passive Immunotherapy Support the Development of a Preventive Vaccine

The apparently near-term effects of the monoclonal antibody BAN2401 in slowing the progression of prodromal Alzheimer's disease (AD) has created cautious optimism about the therapeutic use of antibodies that neutralize cytotoxic soluble amyloid-β aggregates, rather than removing plaque. Plaque...

Descripción completa

Detalles Bibliográficos
Autor principal: Marciani, D. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AAAS 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750119/
https://www.ncbi.nlm.nih.gov/pubmed/31549066
http://dx.doi.org/10.34133/2019/5341375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750119/
https://www.ncbi.nlm.nih.gov/pubmed/31549066
http://dx.doi.org/10.34133/2019/5341375

Ejemplares similares